Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Merck & Co., Inc. reported third-quarter 2026 sales of $18.085 billion, versus $17.276 billion a year earlier, and net income attributable to Merck of $5.065 billion, versus $5.785 billion. For the first nine months, sales were $50.978 billion compared with $48.611 billion, while Merck recorded a $510 million net loss attributable to the company, versus $15.291 billion of income.
First-nine-month research and development expense was $26.871 billion, compared with $11.903 billion. It included charges of $9.0 billion for the Cidara acquisition and $5.7 billion for Terns; both were accounted for as asset acquisitions. Merck acquired Cidara for $9.2 billion and Terns for $6.8 billion.
Operating cash flow for the nine months was $15.846 billion, versus $13.615 billion; investing activities used $17.131 billion, versus $2.540 billion, including acquisition outflows. Merck also closed a worldwide exclusive license for MK-2690, recording a $400 million R&D charge, with the upfront payment expected in the fourth quarter of 2026.
Merck & Co., Inc. director Paul J. Diaz received a grant of 613.073 phantom stock units on November 1, 2026, bringing his directly held phantom stock position to 613.073 units. The reported $149.52 is Merck common stock’s closing price on the business day immediately before the effective date of the director’s service. The units are to be settled 100% in cash upon termination of service under an elected distribution schedule.
Merck & Co., Inc. (MRK) director Paul J. Diaz reported 200 shares of Common Stock held directly and 96 shares held indirectly through his revocable trust, with both holdings dated November 1, 2026.
Merck & Co., Inc. officer David Michael Williams reported an intended sale of 21,359 common shares, with an approximate sale date of November 2, 2026, and an aggregate market value of $3,185,464.17. The shares are listed as acquired from the issuer on November 2, 2026, through exercise of options under a registered plan, with cash payment. Williams also reported sales of 52,847 common shares on August 5, 2026, with an aggregate market value of $6,805,145.18.
Merck & Co., Inc. (MRK) reported third-quarter 2026 sales of $18.085 billion, up 5% from $17.276 billion a year earlier. GAAP net income attributable to Merck fell 12% to $5.065 billion, and diluted GAAP EPS decreased 12% to $2.04. Non-GAAP net income was $6.159 billion, down 4%, while non-GAAP EPS was $2.49, down 3%; both measures exclude specified items.
Pharmaceutical sales increased 4% to $16.268 billion and Animal Health sales rose 4% to $1.676 billion. WINREVAIR sales were $694 million, up 93%, while JANUVIA/JANUMET fell 39% to $380 million and BRIDION fell 67% to $144 million. Gross margin declined to 72.9% from 77.7%; Merck cited higher amortization of intangible assets, restructuring costs and production costs.
Merck updated its full-year 2026 outlook to sales of $66.8 billion to $67.3 billion and non-GAAP EPS of $2.77 to $2.82. The EPS range includes one-time charges of $9.0 billion related to the Cidara acquisition, $5.7 billion related to the Terns acquisition and $400 million related to the SciBrunch license agreement. The outlook also includes positive foreign-exchange impacts of approximately 1% on sales and approximately $0.15 per share on EPS.
Merck & Co., Inc.'s Form 3/A corrects the reported common-stock holding of David R. Maraldo, an officer whose title is EVP & Pres. MMD, in the stock fund of the Merck U.S. Savings Plan. The corrected indirect holding was 2,871 shares as of May 1, 2026. The entry reports a holding balance rather than a purchase or sale.
Merck & Co., Inc.'s 1.875% Notes due 2026 are the subject of a notice to remove them from listing and registration under Section 12(b) on the New York Stock Exchange. The exchange states it complied with its rules to strike the class, and the notice states that the issuer complied with requirements for voluntary withdrawal.
Merck & Co., Inc. (MRK) announced that Paul J. Diaz, managing partner at Cressey & Company, will join its Board of Directors effective November 1, 2026. The Board appointed Diaz to its Audit and Research committees, and his compensation will follow the company’s non-employee director compensation practices. With his addition, the Board will consist of 14 members; Diaz will stand for election by shareholders in May 2027. He previously served as president and chief executive officer of Myriad Genetics and Kindred Healthcare.
Merck & Co., Inc. director Christine E. Seidman acquired 55.9149 phantom stock units through an award on September 30, 2026; the award lists a price of $145.3100 per unit. Her reported post-transaction position was 21,490.4009 phantom stock units, and she separately held 100 shares of common stock directly. The phantom stock units are linked to common stock on a 1-for-1 basis and are to be settled 100% in cash upon termination of service under an elected distribution schedule. Reported holdings include shares acquired in dividend reinvestment transactions.
Merck & Co., Inc. director Surendralal Lanca Karsanbhai reported a grant of 111.8299 phantom stock units on September 30, 2026, with a reported price of $145.3100 per share. The reported phantom-stock balance afterward was 5,667.0117 units. The units are to be settled 100% in cash upon termination of service, following a distribution schedule elected under the Plan for Deferred Payment of Directors’ Compensation. Holdings include shares acquired in dividend reinvestment transactions.